Drugs show efficacy in patients with type 2 diabetes, ESRD

02/1/2013 | Renal and Urology News

Sitagliptin therapy led to a 0.72% reduction in mean A1C levels at 54 weeks, while glipizide treatment resulted in an 0.87% decrease among type 2 diabetes patients with end-stage renal disease who require dialysis, according to a study in the American Journal of Kidney Diseases. Researchers also found the incidence rates of symptomatic hypoglycemia were 6.3% in the sitagliptin group and 10.8% in the glipizide group.

View Full Article in:

Renal and Urology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC